HealthtechBio Tech/Life SciencesDeep TechB2B1-5 employees
PhD FounderActively Raising
VC-Backed FounderGraduate Student Founder
Serial EntrepreneurAbout
Edulis is developing the first therapeutic implant system for sustained, localized treatment of chronic GI conditions like IBD and colorectal cancer. The company positions its platform as a product engine for precision medicine in the gut.
Products
Edulis Submucosal Implant System
A therapeutic implant system for sustained, localized drug delivery to treat chronic GI conditions such as inflammatory bowel disease, GI oncology, and gut microbiome disorders. The submucosal implant is placed endoscopically in under 15 minutes and provides treatment every 6-12 months, reducing the burden of subcutaneous injections, IV infusions, and daily oral pills. Preclinical large animal studies showed up to 80 days of implant retention and good toxicology.
Click to read more